Orexo AB
STO:ORX

Watchlist Manager
Orexo AB Logo
Orexo AB
STO:ORX
Watchlist
Price: 19.26 SEK -0.1% Market Closed
Market Cap: 663.5m SEK
Have any thoughts about
Orexo AB?
Write Note

Net Margin
Orexo AB

-17.7%
Current
-28%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.7%
=
Net Income
-105.3m
/
Revenue
595.8m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Orexo AB
STO:ORX
663.5m SEK
-18%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-79%
US
Eli Lilly and Co
NYSE:LLY
729.3B USD
20%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK
35%
US
Johnson & Johnson
NYSE:JNJ
347.8B USD
17%
US
Merck & Co Inc
NYSE:MRK
248.3B USD
19%
CH
Roche Holding AG
SIX:ROG
197.2B CHF
20%
UK
AstraZeneca PLC
LSE:AZN
159B GBP
13%
CH
Novartis AG
SIX:NOVN
169.7B CHF
35%
US
Pfizer Inc
NYSE:PFE
149.4B USD
7%
Country SE
Market Cap 663.5m SEK
Net Margin
-18%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 729.3B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.6T DKK
Net Margin
35%
Country US
Market Cap 347.8B USD
Net Margin
17%
Country US
Market Cap 248.3B USD
Net Margin
19%
Country CH
Market Cap 197.2B CHF
Net Margin
20%
Country UK
Market Cap 159B GBP
Net Margin
13%
Country CH
Market Cap 169.7B CHF
Net Margin
35%
Country US
Market Cap 149.4B USD
Net Margin
7%
No Stocks Found

Orexo AB
Glance View

Market Cap
663.5m SEK
Industry
Pharmaceuticals

Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

ORX Intrinsic Value
39.21 SEK
Undervaluation 51%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-17.7%
=
Net Income
-105.3m
/
Revenue
595.8m
What is the Net Margin of Orexo AB?

Based on Orexo AB's most recent financial statements, the company has Net Margin of -17.7%.